Literature DB >> 7890302

Soluble TNF receptor production by activated T lymphocytes: differential effects of acute and chronic exposure to TNF.

A P Cope1, D Aderka, D Wallach, M Kahan, N R Chu, F M Brennan, M Feldmann.   

Abstract

Soluble tumour necrosis factor receptors (sTNF-R) are up-regulated at sites of chronic inflammation such as rheumatoid synovial joints. The p75 sTNF-R is the more abundant, suggesting an important role for this TNF inhibitor in regulating TNF bioactivity in vivo. As the precise cellular source of these soluble receptors is not known, we investigated the production and regulation of sTNF-R by T lymphocytes, an abundant cell type in inflammatory infiltrates, which upon activation express high levels of p75 surface receptors. Using panels of T-cell lines and clones expressing high levels of p75 TNF-R, we found that p75 sTNF-R production upon stimulation is a feature common to all subsets of T cells, including cells of the CD4-CD8- double negative phenotype expressing either alpha beta or gamma delta T-cell receptors (TCR). In contrast, levels of p55 sTNF-R were only detected when T cells were stimulated at higher densities and by potent mitogens such as phorbol 12-myristate 13-acetate (PMA). Detailed kinetic analyses revealed that the production of p75 sTNF-R was biphasic, the first phase was activation dependent, occurring in the absence of detectable TNF, while the second phase of p75 sTNF-R production was regulated by cytokines such as TNF. Unlike short-term exposure to TNF which enhances sTNF-R production in vitro and in vivo, prolonged exposure of T lymphocytes to TNF suppressed p75 sTNF-R (but not p55 sTNF-R) production in a dose- and time-dependent fashion. These results suggest that in patients with chronic inflammatory disease, which are exposed to augmented levels of bioactive TNF for prolonged periods, the production of p75 sTNF-R may be impaired.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7890302      PMCID: PMC1415193     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  29 in total

1.  Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans.

Authors:  M Lantz; S Malik; M L Slevin; I Olsson
Journal:  Cytokine       Date:  1990-11       Impact factor: 3.861

2.  Tumor necrosis factor induces a selective shedding of its p75 receptor from human neutrophils.

Authors:  F Porteu; C Hieblot
Journal:  J Biol Chem       Date:  1994-01-28       Impact factor: 5.157

3.  Regulation of tumor necrosis factor (TNF)-alpha synthesis and TNF receptors expression in T lymphocytes through the CD2 activation pathway.

Authors:  A G Santis; M R Campanero; J L Alonso; F Sánchez-Madrid
Journal:  Eur J Immunol       Date:  1992-12       Impact factor: 5.532

4.  Differential regulation of tumour necrosis factor receptors (TNF-R) by IL-4; upregulation of P55 and P75 TNF-R on synovial joint mononuclear cells.

Authors:  A P Cope; D L Gibbons; D Aderka; B M Foxwell; D Wallach; R N Maini; M Feldmann; F M Brennan
Journal:  Cytokine       Date:  1993-05       Impact factor: 3.861

5.  Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus.

Authors:  D Aderka; A Wysenbeek; H Engelmann; A P Cope; F Brennan; Y Molad; V Hornik; Y Levo; R N Maini; M Feldmann
Journal:  Arthritis Rheum       Date:  1993-08

6.  Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases.

Authors:  A P Cope; D Aderka; M Doherty; H Engelmann; D Gibbons; A C Jones; F M Brennan; R N Maini; D Wallach; M Feldmann
Journal:  Arthritis Rheum       Date:  1992-10

7.  Specific induction of 80-kDa tumor necrosis factor receptor shedding in T lymphocytes involves the cytoplasmic domain and phosphorylation.

Authors:  P D Crowe; T L VanArsdale; R G Goodwin; C F Ware
Journal:  J Immunol       Date:  1993-12-15       Impact factor: 5.422

8.  Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.

Authors:  M J Elliott; R N Maini; M Feldmann; A Long-Fox; P Charles; P Katsikis; F M Brennan; J Walker; H Bijl; J Ghrayeb
Journal:  Arthritis Rheum       Date:  1993-12

9.  Gamma interferon enhances macrophage transcription of the tumor necrosis factor/cachectin, interleukin 1, and urokinase genes, which are controlled by short-lived repressors.

Authors:  M A Collart; D Belin; J D Vassalli; S de Kossodo; P Vassalli
Journal:  J Exp Med       Date:  1986-12-01       Impact factor: 14.307

10.  Tumor necrosis factor alpha (TNF-alpha)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type, TNF-R55.

Authors:  F Mackay; H Loetscher; D Stueber; G Gehr; W Lesslauer
Journal:  J Exp Med       Date:  1993-05-01       Impact factor: 14.307

View more
  14 in total

1.  Intravitreal treatment with antisense oligonucleotides targeting tumor necrosis factor-α in murine herpes simplex virus type 1 retinitis.

Authors:  Rafael S Grajewski; Jin Li; Susanne Wasmuth; Maren Hennig; Dirk Bauer; Arnd Heiligenhaus
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-11-10       Impact factor: 3.117

2.  Transmembrane tumor necrosis factor alpha is required for enteropathy and is sufficient to promote parasite expulsion in gastrointestinal helminth infection.

Authors:  M X Ierna; H E Scales; C Mueller; C E Lawrence
Journal:  Infect Immun       Date:  2009-06-29       Impact factor: 3.441

3.  Tumour necrosis factor alpha impairs function of liver derived T lymphocytes and natural killer cells in patients with primary sclerosing cholangitis.

Authors:  X Bo; U Broome; M Remberger; S Sumitran-Holgersson
Journal:  Gut       Date:  2001-07       Impact factor: 23.059

4.  Soluble tumour necrosis factor (TNF)-receptor levels in serum as markers of anti-viral host reactivity.

Authors:  C Bartholdy; A Nansen; O Marker; A R Thomsen
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

Review 5.  Regulation of serum amyloid A protein expression during the acute-phase response.

Authors:  L E Jensen; A S Whitehead
Journal:  Biochem J       Date:  1998-09-15       Impact factor: 3.857

6.  Profile of soluble cytokine receptors in Crohn's disease.

Authors:  T Gustot; A Lemmers; E Louis; C Nicaise; E Quertinmont; J Belaiche; S Roland; A Van Gossum; J Devière; D Franchimont
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

7.  Increased levels of soluble tumor necrosis factor receptors in atherosclerosis: no clear relationship with levels of tumor necrosis factor.

Authors:  A D Blann; C N McCollum
Journal:  Inflammation       Date:  1998-10       Impact factor: 4.092

8.  Differential expression, shedding, cytokine regulation and function of TNFR1 and TNFR2 in human fetal astrocytes.

Authors:  Sun Ju Choi; Kyoung-Ho Lee; Hyun Sook Park; Soo-Ki Kim; Choon-Myung Koh; Joo Young Park
Journal:  Yonsei Med J       Date:  2005-12-31       Impact factor: 2.759

9.  Subconjunctival antisense oligonucleotides targeting TNF-alpha influence immunopathology and viral replication in murine HSV-1 retinitis.

Authors:  Jin Li; Susanne Wasmuth; Dirk Bauer; Hanna Baehler; Maren Hennig; Arnd Heiligenhaus
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-05-20       Impact factor: 3.117

10.  Anti-Pituitary and Anti-Hypothalamus Autoantibody Associations with Inflammation and Persistent Hypogonadotropic Hypogonadism in Men with Traumatic Brain Injury.

Authors:  Sushupta M Vijapur; Zhihui Yang; David J Barton; Leah Vaughan; Nabil Awan; Raj G Kumar; Byung-Mo Oh; Sarah L Berga; Kevin K Wang; Amy K Wagner
Journal:  J Neurotrauma       Date:  2020-04-13       Impact factor: 5.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.